You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Litigation Details for In re: Entresto (Sacubitril/Valsartan) Patent Litigation (D. Del. 2020)

✉ Email this page to a colleague

« Back to Dashboard

In re: Entresto (Sacubitril/Valsartan) Patent Litigation (D. Del. 2020)

Docket	⤷ Sign Up	Date Filed	2020-03-27
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Parties	LUPIN LIMITED
Patents	10,004,746; 10,010,507; 10,016,435; 10,106,548; 10,125,140; 10,213,386; 10,294,231; 10,294,232; 10,335,462; 7,342,117; 7,468,390; 7,514,444; 7,879,828; 7,982,049; 8,008,309; 8,101,659; 8,404,744; 8,476,284; 8,497,277; 8,563,563; 8,679,069; 8,697,711; 8,703,780; 8,735,403; 8,754,090; 8,754,091; 8,796,331; 8,877,938; 8,952,015; 8,957,079; 8,999,999; 9,125,889; 9,181,257; 9,296,753; 9,388,134; 9,540,382; 9,655,857; 9,713,617; 9,725,455; 9,795,604; 9,801,881; 9,801,883; 9,814,721
Attorneys	James T. Peterka
Firms	Young, Conaway, Stargatt & Taylor LLP
Link to Docket	External link to docket

Small Molecule Drugs cited in In re: Entresto (Sacubitril/Valsartan) Patent Litigation

The small molecule drugs covered by the patents cited in this case are ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , and ⤷ Sign Up .

Biologic Drugs cited in In re: Entresto (Sacubitril/Valsartan) Patent Litigation

The biologic drugs covered by the patents cited in this case are ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , and ⤷ Sign Up .

Details for In re: Entresto (Sacubitril/Valsartan) Patent Litigation (D. Del. 2020)

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign Up
Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2019-03-01	1	Complaint	PageID #: 2 Patent”); 9,655,857 (“the ’857 Patent”); 9,725,455 (“the ’455 Patent”); 10,010,507 (“the ’507… United States Patent Nos. 7,514,444 (“the ’444 Patent”); 8,008,309 (“the ’309 Patent”); 8,476,284 (“…(“the ’284 Patent”); 8,497,277 (“the ’277 Patent”); 8,697,711 (“the ’711 Patent”); 8,735,403 (“the ’403…’403 Patent”); 8,754,090 (“the ’090 Patent”); 8,754,091 (“the ’091 Patent”); 8,952,015 (“the ’015 Patent…507 Patent”); 10,106,548 (“the ’548 Patent”); and 10,125,140 (“the ’140 Patent”).	External link to document
2023-06-01	1057	Proposed Order	pediatric exclusivity for U.S. Patent No. 8,404,744 (“the ’744 patent”) expires on July 14, 2023, which… patent or the ’667 patent] [Noratech’s proposal: if such deposition concerned the ’659 patent or… proposal: the validity of] the ’659 patent or the ’667 patent, (ii) Novartis’s documents concerning…proposal: the validity of] the ’659 patent or the ’667 patent, and (iii) the deposition testimony (including…Asserted Patent. Novartis will produce to Noratech the file history for the ’659 and ’667 patents within	External link to document
2023-06-02	1058	Redacted Document	United States Patent No. 8,101,659 (“the ’659 Patent”), of United Sates Patent No. 8,877,938…the ’938 Patent”), of United States Patent No. 9,388,134 (“the ’134 Patent”), …United States Patent No. 11,058,667 (“the ’667 Patent”), and of United States Patent No. 11,096,918…the ’659 Patent, of the ’938 Patent, of the ’134 Patent, … of the ’667 Patent, and of the ’918 Patent are valid and enforceable. 2. Judgment	External link to document
2023-06-02	1059	Redacted Document	of United States Patent No. 8,101,659 ("the ' 659 Patent"), … of United Sates Patent No. 8,877,938 ("the ' 938 Patent"), of…of United States Patent No. 9,388,134 ("the' 134 Patent"), … ofUnited States Patent No . 11 ,058,667 ("the ' 667 Patent"), and ofUnited… ofUnited States Patent No. 11 ,096,918 ("the ' 918 Patent") are valid and enforceable	External link to document
2023-06-05	1063	Exhibit A-C	21 C.F.R. § 314.95 of U.S. Patent Nos. 7,468,390, 8,101,659, 8,404,744, 8,796,331, 8,877,…strengths, before the expiration of U.S. Patent Nos. 7,468,390, 8,101,659, 8,404,744, 8,796,331, 8,877,… paragraph IV certification are U.S. Patent Nos. 7,468,390, 8,101,659, 8,404,744, 8,796,331, 8,877,… Patent Expiry 7,468,390 Novartis AG 11/27/2023 …to the best of their knowledge, U.S. Patent Nos. 7,468,390, 8,101,659, 8,404,744, 8,796,331, 8,877,938	External link to document
2023-07-07	1099	Opinion	infringement of U.S. Patent 8,877,938 (the “’938 Patent”), 9,388,134 (the “’134 Patent”), 8,101,659 (the “’659 …659 Patent”) and 8,796,331 (the “’331 Patent”). Only the ’659 Patent is at issue in this opinion. The parties… of that patent. (/d.). I held separate trials addressing the ’938 Patent and the ’134 Patent. (D.I. 604…Ciba-Geigy, was issued U.S. Patent No. 5,399,578 (“the ’578 Patent”). (JTX-23). That patent disclosed and claimed…the °659 Patent claims are obvious over EP ’072, the ’996 Patent/Ksander, and the °578 Patent/Diovan®	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.